#JPM21: Albert Bourla prepares Pfizer to settle in to next phase post-Upjohn, but that doesn't mean he's ruling out deals
One of the iconic brands in biopharma, Pfizer took a big gamble on the strength of its in-house science when it decided to offload its flagging Upjohn generics business last year. Now, a more agile Pfizer is looking to cement its identity for the future, but one thing will stay the same: M&A is still very much a part of the game plan.
With its Upjohn generics business off the books, Pfizer is looking to double down on its branded medicines with the goal of hitting 6% annual growth each year — previously unheard-of at old Pfizer — while continuing to develop its blockbuster pipeline, CEO Albert Bourla said at a JP Morgan fireside chat Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.